Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · IEX Real-Time Price · USD
0.930
+0.040 (4.49%)
At close: May 17, 2024, 4:00 PM
0.920
-0.010 (-1.08%)
After-hours: May 17, 2024, 7:59 PM EDT

Company Description

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada.

It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.

The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer.

It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products.

In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications.

Sunshine Biopharma, Inc. is headquartered in New York, New York.

Sunshine Biopharma, Inc.
Sunshine Biopharma logo
Country Canada
Founded 2006
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 44
CEO Dr. Steve N. Slilaty Ph.D.

Contact Details

Address:
1177 Avenue Of The Americas, 5th Floor
New York, New York 10036
United States
Phone 332-216-1147
Website sunshinebiopharma.com

Stock Details

Ticker Symbol SBFM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001402328
CUSIP Number 867781304
ISIN Number US8677814035
Employer ID 20-5566275
SIC Code 2834

Key Executives

Name Position
Camille Sebaaly Chief Financial Officer and Secretary
Dr. Abderrazzak Merzouki Chief Science Officer and Director
Dr. Steve N. Slilaty Ph.D. Chief Executive Officer, President and Chairman
Marc Beaudoin Chief Operating Officer
Malek Chamoun Chief Development Officer
Robert G. Ferreira President of Sunshine Bio Investments Inc

Latest SEC Filings

Date Type Title
May 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
May 8, 2024 8-K Current Report
May 6, 2024 8-K Current Report
Apr 23, 2024 8-K Current Report
Apr 1, 2024 8-K Current Report
Mar 28, 2024 10-K Annual Report
Mar 15, 2024 DEF 14C Filing
Mar 6, 2024 8-K Current Report
Mar 5, 2024 PRE 14C Filing
Mar 5, 2024 DEF 14C Filing